Qiming Venture Partners Weekly | Portfolio Company Updates and Funding News Vol. 22, 2025
Following Qiming Venture Partners' portfolio companies' milestone moments with you
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to join us in following the milestone moments of our portfolio companies.
Corporate ESG
Dingke Medical Donates RMB 500,000 in Special Charitable Funds
Co-launches "Patient Care Project — Pure Life Public Welfare Classroom"
Recently, Qiming Venture Partners portfolio company Dingke Medical donated RMB 500,000 in special charitable funds to the Beijing Kangmeng Charity Foundation, partnering with the Vascular Access Specialist Group of the Chinese Hospital Association's Blood Purification Center Branch to co-launch the "Patient Care Project — Pure Life Public Welfare Classroom." The full amount of this donation will be used to support grassroots hemodialysis access screening, free surgeries, technical training, and patient assistance, addressing grassroots diagnostic and treatment challenges through a systematic public welfare model.
In the first phase of activities, an expert team led by Professor Yuzhu Wang, a vascular access specialist at Beijing Haidian Hospital, went deep into Weifang Hanting District People's Hospital and surrounding hospitals in Shandong Province. Through a four-in-one model of "screening — surgery — training — donation," they built a lifeline of health protection for grassroots hemodialysis patients. The project aims to elevate grassroots vascular access diagnosis and treatment standards and genuinely care for the health of dialysis patients.
Funding News
Galaxy Universal Closes New RMB 1.1 Billion Funding Round
Recently, Qiming Venture Partners portfolio company Galaxy Universal announced the formal completion of a new RMB 1.1 billion funding round, bringing its total funding to over RMB 2.4 billion in just two years.
Since its founding, Galaxy Universal has pioneered a technical paradigm of pre-training with simulated synthetic action datasets and post-training with real-world data, leading the rapid iteration of global embodied large-model technology. Its breakthrough achievements include launching GraspVLA, the world's first end-to-end embodied large model pre-trained on billion-level simulated synthetic action data; GroceryVLA, the world's first end-to-end model for retail commercialization; and TrackVLA, a product-grade end-to-end navigation large model.
In terms of scaled robot application deployment, Galaxy Universal has made significant progress in smart retail, industrial, and healthcare scenarios.
At BAAI's "2025 BAAI Conference," He Wang, assistant professor at Peking University, founder and CTO of Galaxy Universal, and BAAI scholar, emphasized: "The core goal of embodied intelligence right now is to resolutely achieve industrial breakthroughs." As a global leader in embodied large-model research and a pioneer in general-purpose robot industrial deployment, Galaxy Universal is accelerating the continuous transformation of embodied large-model robotics technology into productive force.
Major Partnerships
01/
Galaxy Universal Partners with Bosch China and Others
to Establish Joint Venture "Boyin Hechuang"
Recently, Bosch and Qiming Venture Partners portfolio company Galaxy Universal formally announced the establishment of joint venture "Boyin Hechuang." The joint venture will focus on complex assembly, intelligent quality inspection, and other high-precision manufacturing scenarios, developing dexterous robots and driving the scaled deployment of embodied artificial intelligence in industrial settings. At the same time, the joint venture will actively pursue fundraising expansion and global layout, building an internationally competitive smart manufacturing product system. This cooperation comes at a critical juncture as global manufacturing accelerates toward intelligentization, marking an important milestone for embodied intelligence technology's transition from experimental validation to industrial deployment.
As one of the first fruits of this cooperation, the joint venture "Boyin Hechuang" also signed a strategic cooperation memorandum on-site with United Automotive Electronic Systems Co., Ltd., announcing the joint establishment of the embodied intelligent robot joint laboratory "RoboFab." The laboratory will focus on exploring robotic intelligent perception, operational control, and system deployment in typical automotive manufacturing processes,打通 from algorithm models to production systems to form a complete closed-loop process and accelerate the scaled deployment of embodied intelligent robots in the automotive industry.
02/
Infinigence AI Signs Cooperation Agreement with Huawei Cloud
During Huawei Developer Conference 2025 (HDC 2025), Qiming Venture Partners portfolio company Infinigence AI formally signed a comprehensive cooperation agreement with Huawei Cloud. The two parties will carry out in-depth cooperation around heterogeneous computing platforms, Ascend computing clusters, large model adaptation R&D, and industry solutions, jointly advancing AI computing technology innovation and ecosystem collaboration.
The two parties will also conduct comprehensive cooperation in solution synergy, AI large models, and cloud services. Infinigence AI will deeply integrate its industry-leading solutions with Huawei Cloud's ecosystem platform, jointly exploring heterogeneous computing scheduling tailored to industries, best practices for large model training, and joint solutions. Meanwhile, both sides will expand and strengthen the depth and breadth of ecosystem cooperation, promoting openness to industries and working together to empower sectors and continuously enrich the ecosystem. Huawei Cloud will also support Infinigence AI in advancing the落地 of AI large models and Ascend computing research, promoting the productization of IaaS/PaaS services, and jointly enhancing customer business value and core competitiveness.
03/
Unisound and SenseTime Reach Strategic Cooperation
Recently, Qiming Venture Partners portfolio company Unisound and SenseTime formally signed a strategic cooperation agreement. Based on their respective technical accumulations and resource advantages, the two parties will carry out in-depth cooperation around multimodal large models, industry applications, and intelligent terminals, exploring the落地 practice of large models in vertical industries. Through deep fusion of model capabilities, both sides will collaborate on innovation in multimodal interaction spanning voice and vision, providing industry customers with more natural and efficient intelligent interaction experiences, accelerating the scaled deployment of intelligent technology, and driving intelligent upgrades across multiple industries.
Unisound has consistently深耕 the cutting edge of AI, gradually building a full-stack AI硬核 technical system encompassing large model technology, multimodal interaction technology, AI chips, and domain knowledge graphs, and successfully applying these technical achievements to medical, transportation, smart home, and other physical scenarios. Its self-developed "Shanhai Large Model" ranks among the world's top in general capabilities, with professional capabilities in medical and other fields reaching world-leading levels. It has also expanded multimodal interaction capabilities including text-to-image and audio-image Q&A, significantly broadening application boundaries. With the "Shanhai Large Model" at its core, Unisound's industry intelligent agents have been widely applied in vertical domains such as assisted diagnosis and treatment, medical insurance claims verification, and intelligent vehicle cabins.
04/
Hesai Technology LiDAR Powers
2026 Leapmotor C16 Launch
Recently, the 2026 Leapmotor C16 was officially launched. For assisted driving, all six trim levels are equipped with 28 intelligent perception hardware units including LiDAR from Qiming Venture Partners portfolio company Hesai Technology (NASDAQ: HSAI), enabling detection that is farther, wider, and more precise.
Going forward, Hesai Technology will continue to deepen its strategic partnership with Leapmotor, empowering the full lineup of Leapmotor vehicles with industry-leading perception capabilities that give family SUVs stronger, more comprehensive all-scenario mobility.
05/
Lattice Power and TÜV Rheinland Enter Strategic Partnership to Advance Perovskite Photovoltaic Technology
During the 2025 Shanghai SNEC International Photovoltaic Power Generation and Smart Energy Conference, Germany's TÜV Rheinland and Qiming Venture Partners portfolio company Lattice Power formally signed a strategic cooperation agreement.
Under the agreement, the two parties will collaborate extensively on performance testing and certification of perovskite photovoltaic modules and materials, accelerated aging and reliability assessment, empirical power generation data analysis, and industry standard research and formulation — jointly advancing the quality evaluation system for perovskite photovoltaic technology and its commercial application.
06/
DST New Energy and ZhongAn Sign Strategic Partnership to Establish New Energy Vehicle Joint Risk Control Lab
Recently, Qiming Venture Partners portfolio company DST New Energy and ZhongAn signed a strategic cooperation agreement in Shenzhen, Guangdong.
The "New Energy Vehicle Joint Risk Control Lab," led by both parties, was officially inaugurated. The lab aims to jointly explore and build an integrated "Technology + Data + Service" risk control system, creating an industry model that reduces costs, improves efficiency, and keeps risks manageable. It will provide logistics companies, driver communities, and cargo owners with more efficient, more assured services, injecting strong momentum into the future development of the green logistics industry.
Frontage Laboratories' Wholly-Owned Subsidiary Enters Strategic Partnership with VasoDynamics
Recently, the wholly-owned subsidiary of Qiming Venture Partners portfolio company Frontage Laboratories, Frontage Pharma, formally entered a strategic partnership with Europe's VasoDynamics. Going forward, both parties will establish a long-term strategic partnership for contract technical development and manufacturing of special dosage forms such as mouthwash and topical solutions during the clinical trial phase and subsequent commercialization phase.
Frontage Laboratories primarily provides drug R&D, analytical services, clinical sample manufacturing, clinical packaging and supply, stability studies, and regulatory filing services. Frontage Laboratories' GMP manufacturing facility in Suzhou can produce tablets, capsules, granules, oral solutions, eye drops, inhalation products, injections, lyophilized formulations, creams, ointments, and hormone products with special requirements.
R&D Progress
Gan & Lee Pharmaceuticals Presents Promising Data for Biweekly GLP-1RA Bofanglutide at ADA 85th Scientific Sessions
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that it presented multiple Phase 2 clinical study results for its self-developed ultra-long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) bofanglutide (development code: GZR18) injection in Chinese patients with type 2 diabetes (T2DM) at the 2025 American Diabetes Association 85th Scientific Sessions (ADA 2025) in poster format.
The latest clinical results presented at this year's ADA meeting highlight Gan & Lee Pharmaceuticals' leading position in developing long-acting glucose-lowering drugs. Building on these positive clinical outcomes, the company will further advance R&D of innovative diabetes treatments. Gan & Lee Pharmaceuticals has already initiated and is accelerating large-scale Phase 3 series studies of bofanglutide injection for the type 2 diabetes indication in China, aiming to bring better treatment options to patients with diabetes.
Insilico Medicine Doses First Patient with ISM3412
Recently, Qiming Venture Partners portfolio company Insilico Medicine announced that it has dosed the first patient in a global multi-center clinical trial (NCT06414460) evaluating the AI-enabled, novel-structured, potentially best-in-class MAT2A inhibitor ISM3412 in patients with locally advanced and metastatic solid tumors.
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, stated: "We are pleased to see that ISM3412, developed with AI technology, has the potential to provide innovative treatment options for patients with advanced or metastatic tumors. We look forward to newer, more efficient treatment strategies bringing benefits to patients worldwide."
Insilico Medicine's Research on Novel Chemical Structure Pan-KRAS Inhibitors Published in International Journal
Recently, Qiming Venture Partners portfolio company Insilico Medicine announced that it has successfully developed a series of pan-KRAS inhibitors with novel chemical structures through its proprietary generative chemistry platform Chemistry42, employing structure-based drug design, scaffold hopping, deep molecular modeling, and other strategies. The resulting candidate compound series was driven by the combination of artificial intelligence technology and human expertise, demonstrating high nanomolar pan-KRAS inhibitory activity. The related research results were recently published in ACS Medicinal Chemistry Letters, a journal of the American Chemical Society (ACS).
Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, stated: "We are delighted to see the transformation that Insilico Medicine's AI-driven Chemistry42 generative chemistry platform is bringing to the drug discovery field. This research highlights how molecular modeling and scaffold hopping can work on highly challenging targets such as KRAS, which was previously considered 'undruggable,' further validating the potential of AI technology to accelerate molecular development and optimization."
SinoCellTech's SCTB39-1 Injection Approved by National Medical Products Administration for Clinical Trials
Recently, Qiming Venture Partners portfolio company SinoCellTech (688520.SH) announced that its SCTB39-1 injection has received approval from China's National Medical Products Administration to conduct clinical trials as a monotherapy for patients with advanced malignant solid tumors.
SCTB39-1 is a multi-target immunotherapy trispecific antibody injection developed independently by SinoCellTech.
CanSino Biologics Co-Develops Three-Component Lipid Nanoparticle Delivery System
Recently, Qiming Venture Partners portfolio company CanSino Biologics (688185.SH, 06185.HK), in collaboration with the R&D team at Beijing JenKem Technology Co., Ltd., successfully developed a three-component lipid nanoparticle (ISL-3C-LNP) delivery system based on a novel ionizable sterol lipid (ISL). Through rational design and systematic screening, the team obtained a series of ISL compounds with excellent properties. The research was published in the international authoritative journal ACS Applied Materials & Interfaces.
The results showed that ISL-3C-LNP significantly improved safety and enhanced cellular immune responses, while offering simplified composition and patent advantages.
This innovative delivery system provides a new technical option for mRNA vaccine development, demonstrating important application value particularly in therapeutic areas requiring strong cellular immune responses, such as tumor immunotherapy. The development of ISL-3C-LNP not only addresses the patent limitations of traditional LNPs, but its enhanced immunogenicity and improved safety profile also offer new directions for the design of next-generation mRNA vaccines.
InventisBio's Garsorasib Study for Advanced or Metastatic Colorectal Cancer Published in International Journal
Recently, Qiming Venture Partners portfolio company InventisBio (688382.SH) announced progress in its independently developed, highly selective KRAS G12C oral inhibitor garsorasib for treating KRAS G12C-mutated advanced solid tumors. The study was led by Professor Ruihua Xu at Sun Yat-sen University Cancer Center, and the colorectal cancer (CRC) cohort results were formally published in the international journal Signal Transduction and Targeted Therapy (impact factor: 40.8).
The results showed that garsorasib monotherapy or in combination with cetuximab demonstrated favorable efficacy and safety in advanced or metastatic CRC. In the garsorasib monotherapy cohort, the objective response rate (ORR) was 19.2%, disease control rate (DCR) was 92.3%, median progression-free survival (PFS) was 5.5 months, and median overall survival (OS) was 13.1 months. In the garsorasib plus cetuximab cohort, ORR reached 45.2%, DCR was 92.9%, median PFS was 7.5 months, and median OS was not yet reached.
07/
Zhenluo Science Collaborative Research Published in Nature Sub-Journal npj Digital Medicine
Recently, a research team led by Professor Zhiwei Luo and Professor Changqin Quan at Kobe University, in collaboration with Qiming Venture Partners portfolio company Zhenluo Science, published their findings in the Nature journal npj Digital Medicine (impact factor: 15.1).
Voice-based Parkinson's disease (PD) detection faces two core challenges: first, data privacy concerns make centralized data sharing difficult; second, significant differences in phonetic features across languages make it hard for models to cover multiple languages. The FedOcw framework proposed in this study creatively addresses these issues through dynamic client weight optimization and cross-lingual feature extraction mechanisms, achieving PD diagnostic performance that significantly surpasses local models and other federated learning methods on multi-language datasets.
Corporate Development
Fudong Musculoskeletal Yangpu Clinic Completes Service Upgrade
Recently, Qiming Venture Partners portfolio company Fudong Musculoskeletal announced that its Yangpu clinic has officially launched evening outpatient services, while continuing to provide Shanghai medical insurance designated services, further reducing the burden of medical expenses.
Fudong Musculoskeletal focuses on providing orthopedic and sports medicine perioperative rehabilitation, sports injury and conservative treatment rehabilitation, musculoskeletal chronic pain treatment, professional sports guidance and performance enhancement, female pregnancy and postpartum musculoskeletal rehabilitation, pediatric growth and development assessment and correction, and professional geriatric rehabilitation services. Through Fudong Musculoskeletal's online remote rehabilitation services, patients can undergo personalized rehabilitation training under the guidance of the professional team without traveling long distances, with real-time monitoring of rehabilitation progress and timely adjustment of treatment plans to maximize rehabilitation outcomes, making rehabilitation treatment more convenient, efficient, and precise.
Product Launches
01/
Nurotron Officially Releases 3.0T MRI-Compatible Cochlear Implant System
Recently, Qiming Venture Partners portfolio company Nurotron officially released its globally leading 3.0T MRI-compatible cochlear implant system. The launch of this breakthrough product marks a leap forward for China in the field of high-end auditory implant devices.
The product's technical advantages include: a slim implant body requiring minimal bone drilling; small artifact area; unlimited MRI scan frequency, with a uniquely threaded magnet design for easy insertion and removal when head scans are needed; industry-leading data transmission rates for richer, fuller sound content; and a special electrode lead design that improves tensile performance by 80% over the previous generation, so pediatric patients need not worry about changes in head circumference as they grow.
Nurotron CEO Chu Li said: "Nurotron has always been mission-driven to 'help people with hearing loss regain sound,' insisting on both independent innovation and international cooperation. In recent years, our products have not only achieved breakthroughs in the Chinese market, but have also conducted clinical collaborations in Europe, Asia, and other regions, gradually building a global service network. Going forward, Nurotron will continue to deepen cooperation with top global medical institutions and experts to promote the inclusive development of auditory implant technology."
02/
CanSino Biologics' 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Upexin® Formally Approved
Recently, the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13i) Upexin®, independently developed by Qiming Venture Partners portfolio company CanSino Biologics (688185.SH, 06185.HK), formally received approval from China's National Medical Products Administration. It becomes China's first pneumococcal polysaccharide conjugate vaccine to use both diphtheria toxin non-toxic mutant (CRM197) and tetanus toxoid (TT) as dual carriers.
Unlike pneumococcal conjugate vaccines already on the market in China, Youpeixin® effectively avoids adverse reactions that may result from excess single-carrier use, reduces immune interference when co-administered with other vaccines, and enhances immunogenicity. Additionally, the vaccine provides superior protection against the four serotypes (19F, 19A, 7F, and 3) that impose the heaviest disease burden on Chinese children.
03/
Qiming Venture Partners Portfolio Company Burning Rock's PD-L1 Companion Diagnostic Kit Approved for New Indication
Following its approval for non-squamous non-small cell lung cancer (nsNSCLC), Qiming Venture Partners portfolio company Burning Rock has received formal approval for its PD-L1 companion diagnostic kit for a new indication: esophageal squamous cell carcinoma (ESCC). This indication was co-developed by Burning Rock and Henlius, and is designed to aid in identifying ESCC patients eligible for treatment with HANSIZHUANG® (serplulimab injection) — serving as a companion diagnostic for HANSIZHUANG® (PD-L1 positive standard: CPS≥1). This approval represents not only a milestone in technological innovation, but also a transformation in the paradigm of precision treatment for esophageal cancer, marking a critical step forward in Burning Rock's market expansion.
Burning Rock has developed two PD-L1 clone antibody companion diagnostic products tailored to different sponsors' pipelines. Its approved indications now cover three of the most prevalent tumor types — lung cancer, breast cancer (TNBC), and esophageal cancer — establishing the company as a leader in domestic companion diagnostic reagents. The PD-L1 antibody reagents are also compatible with multiple platform detection devices and have received recommendations from authoritative pathology expert consensus.
Technology & Innovation
01/
Three Qiming Venture Partners Portfolio Companies Selected for Ifenxi's 2025 AIGC Vendor Panorama Report
Ifenxi recently released its 2025 Ifenxi AIGC Vendor Panorama Report, aiming to reveal the application of generative AI (AIGC) technology in specific domains and the core competitiveness of representative vendors. Qiming Venture Partners portfolio companies Shengshu Technology, Zuoyi Technology, and Zhipu AI were selected for the report.
To qualify for inclusion, vendors' products and services had to meet Ifenxi's capability requirements for each market segment analyzed; vendors also needed to have secured a certain number of enterprise paying customers between Q2 2024 and Q1 2025, with revenue in specific markets meeting designated thresholds.
02/
DeepWay Participates in 2025 Express Industry Intelligent New Energy Heavy-Duty Truck Application Exchange Conference
At the "2025 Express Industry Intelligent New Energy Heavy-Duty Truck Application Exchange Conference" co-hosted by China Communications Press and STO Express, Qiming Venture Partners portfolio company DeepWay co-founder and CMO Shangshang Xu shared insights on "Customized Pathways for New Energy Heavy-Duty Trucks in Express Delivery Scenarios."
He emphasized DeepWay's product philosophy of adhering to ground-up development and staying closely attuned to express transportation needs. On the electrification front, the vehicles are equipped with 600 kWh high-capacity batteries, delivering over 500 km of range with ultra-low power consumption and maximized cargo space, significantly reducing operating costs. On the intelligence front, the vehicles feature L2-level advanced driver-assistance systems, supporting adaptive cruise control, lane keeping, and other functions that effectively enhance driving safety and operational efficiency.
03/
iMile Demonstrates Strong Logistics Capabilities During Mexico's Hot Sale E-Commerce Event
Qiming Venture Partners portfolio company iMile announced that during Mexico's annual e-commerce event, Hot Sale, its parcel processing volume surged 81.82% year-over-year. Despite this spike, iMile maintained delivery of over 90% of parcels within six days, with average signed-for delivery time improving 25% compared to the same period last year — demonstrating robust logistics service capabilities.
As one of the earliest emerging-market tech logistics companies to establish operations in Mexico, iMile has focused on building core competencies in fulfillment, establishing an efficient nationwide logistics network. The company has set up core transfer centers in Mexico City, Guadalajara, and Monterrey, constructing an intelligent transshipment system through multiple injection points to ensure rapid, efficient last-mile delivery across the country. All hubs are equipped with automated sorting equipment, with capacity up 300% year-over-year, providing strong support for peak scenarios such as major sales events. Combined with its proprietary T1 customs clearance license and self-built last-mile delivery system, iMile achieves full-chain transparency and control, offering e-commerce sellers comprehensive intelligent logistics solutions.
04/
Pulnovo Medical's PADN Product Series Debuts at India's CHIP INDIA SUMMIT
As Qiming Venture Partners portfolio company Pulnovo Medical completed its first three overseas commercial PADN (Percutaneous Pulmonary Artery Denervation) procedures in the UAE, its PADN product series simultaneously debuted at India's CHIP INDIA SUMMIT — attracting local cardiovascular specialists' attention through live surgical broadcasts. With this "dual-track" approach, Pulnovo Medical is steadily advancing its original technology into more real-world clinical settings and academic platforms, accelerating its global strategy.
PADN was presented at the conference via remote broadcast, with a surgical team from Nanjing First Hospital in China demonstrating the procedure and operational details. Multiple experts expressed strong interest in the technology following the session, particularly noting its "minimally invasive intervention + sympathetic modulation" mechanism as offering a novel therapeutic approach for pulmonary hypertension — one worth further exploring for implementation in South Asia.
PADN's impressive presentation at the conference earned high recognition from local Indian medical institutions and industry partners. Compared to mature markets, emerging countries like India face massive unmet needs in pulmonary hypertension, with large patient populations and limited treatment options. PADN's distinctive advantages of being "minimally invasive and safe" provide local physicians and patients with a new solution.
05/
Nurotron Debuts at European Symposium on Pediatric Cochlear Implantation
At the European Symposium on Pediatric Cochlear Implantation (ESPCI 2025), Qiming Venture Partners portfolio company Nurotron showcased its self-developed latest technologies and products, engaging with global experts on the future of the industry.
Professor Li Yin, Nurotron's Chief Medical Officer, delivered important academic presentations over three consecutive days. Three studies demonstrated the clinical value of Nurotron's products from different dimensions. Nurotron also exhibited its newly released MRI-compatible cochlear implant and the Airum all-in-one speech processor with clear sound technology.
06/
Zhenluo Science Presents at 18th Annual Meeting of Chinese Neurologists Association
At the 18th Annual Meeting of the Chinese Neurologists Association, Qiming Venture Partners portfolio company Zhenluo Science, as an innovative medical technology company in the neurological disease space, was invited to participate in the conference's innovation showcase — presenting its systematic solutions for Parkinson's disease and related conditions that cover both hospital and home settings across the full diagnosis and treatment cycle.
The Zhenluo Science team systematically demonstrated how MATRIX Pro leverages integrated sensing technology and intelligent algorithms to address the complex and varied demands of clinical quantitative assessment and assisted diagnosis.
Zhenluo Science also showcased GYENNO Intelligence, a full-scenario medical AI system for Parkinson's disease that fully empowers every technology and service within the GYENNO ecosystem. Its intelligent medical consultation service for patients addresses information needs between clinical visits, offering round-the-clock, interactive Q&A that covers disease education, treatment plan analysis, and follow-up report interpretation — helping patients improve their health literacy and self-management capabilities. Through convenient access via mobile smart devices, it effectively fills the information gap during "non-appointment periods."
07/
HaiheHeart Helps Zhejiang University School of Medicine's Second Affiliated Hospital Redesign Its Day Chemotherapy Center
With technology and service support from HaiheHeart, a Qiming Venture Partners portfolio company, the Day Chemotherapy Center at the Second Affiliated Hospital of Zhejiang University School of Medicine successfully transformed patient flow from "three visits required" to "half-day completion." Patients' time in hospital dropped dramatically, while their quality of life and treatment adherence improved significantly.
Leveraging innovative AI capabilities and China's leading experience in building intelligent whole-journey cancer management systems, HaiheHeart played a deep role in redesigning the Day Chemotherapy Center's clinical workflow, integrating humanistic care into treatment processes and pushing cancer care toward greater efficiency and patient-centeredness.
Since its launch in 2021, the Day Chemotherapy Center has cumulatively treated 48,095 patient visits, reduced average in-hospital waiting time by 120–180 minutes, achieved a peak daily bed utilization rate of 312.90%, and maintained monthly bed utilization at 231.64%. HaiheHeart will continue its deep collaboration with the Second Affiliated Hospital to extend the Day Chemotherapy Center's high-quality services to additional campuses, jointly building a benchmark for day chemotherapy nationwide.
Company Honors
01/
Yunji Technology Wins Special Jury Gold Medal at the 50th Geneva International Exhibition of Inventions
At the 50th Geneva International Exhibition of Inventions, Yunji Technology, a Qiming Venture Partners portfolio company, received the "Gold with the Congratulations of the Jury" for its core technology breakthroughs. The awardees included Zhi Tao, founder, chairman, and president of Yunji Technology.
This award requires unanimous jury approval and represents the highest level of recognition at the exhibition. As an industry benchmark, Yunji Technology's "UP+HDOS" demonstrated the convergence potential of multi-form robot terminals with general-purpose intelligent systems, advancing service robots from single-unit intelligence to swarm intelligence and providing new momentum for industry digital transformation. This honor recognizes not only Yunji Technology's innovation capabilities but also affirms the results of its "AI + Embodied Artificial Intelligence" strategy.
02/
Epicrisis Biotech Wins Third Prize at the 2025 North American Biomedical Pitch Competition
In the finals of the 2025 North American Biomedical Pitch Competition, Epicrisis Biotech, a Qiming Venture Partners portfolio company, stood out from 170 global teams to win third prize for its breakthrough epigenetic therapeutics and innovative business model.
The competition gathered the world's most promising biomedical innovators, with teams delivering professional roadshows and demonstrations evaluated on dimensions including technological innovation and clinical translation potential.
Dr. Baohong Zhang, co-founder and CEO of Epicrisis Biotech, said: "We are deeply honored to receive this recognition on the international stage. Going forward, we will continue to advance in the epigenetics field, accelerating the development of innovative therapies to bring more efficient and precise treatment options to patients worldwide."
Previous Issues
Qiming Weekly | Qiming Venture Partners Portfolio Updates Vol. 21, 2025 In Conversation | StepFun Ventures Into Uncharted Territory in AI Entrepreneurship
In Conversation | Glimpsing the Future of the Humanoid Robotics Industry
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.